A pattern is emerging across teams, products, and markets — and it changes how serious people should think about the truth about continuous glucose monitors for non-diabetics.
What's changing
The shift began quietly. A handful of teams, working in parallel and mostly unaware of each other, arrived at similar conclusions: the old approach optimized for a constraint that no longer binds. Hardware got cheaper. Models got smaller. Distribution got more direct. Each individual change felt incremental — but together they reset the cost curve.
Why it matters
The shift began quietly. A handful of teams, working in parallel and mostly unaware of each other, arrived at similar conclusions: the old approach optimized for a constraint that no longer binds. Hardware got cheaper. Models got smaller. Distribution got more direct. Each individual change felt incremental — but together they reset the cost curve.
What to do about it
If you talk to the practitioners actually shipping in this space, they sound notably less excited and notably more confident than the hype cycle suggests. That contrast — quieter, more grounded enthusiasm — is usually the signal you want.
- Adopt early — the cost of waiting is higher than the cost of failing fast.
- Measure honestly — pick two metrics, ignore the rest for the first month.
- Talk to users — the gap between assumption and reality is wider than ever.
The takeaway
If you take one thing away: the asymmetry has flipped. The risk used to be over-investing. Now it's under-investing while convincing yourself you're being prudent.
